Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

319
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
319
Angina V: Nursing Management01:20

Angina V: Nursing Management

193
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
193
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

128
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
128
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

93
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
93
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.1K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

717
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
717

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Primary percutaneous coronary intervention within the first hour: Insights from early-treated patients with ST-elevation myocardial infarction.

American heart journal·2026
Same author

Rescue percutaneous coronary intervention in the pharmaco-invasive era of ST-elevation myocardial infarction: insights from the STREAM-2 trial.

European heart journal. Acute cardiovascular care·2025
Same author

Association of study visit interval length with follow-up completeness and adherence to assigned study drug dose: A randomized comparison of participants in the ADAPTABLE trial.

Contemporary clinical trials·2025
Same author

Pharmaco-invasive strategy and dosing of tenecteplase in STEMI patients 60 to <75 years: An inter-trial comparison of the STREAM-1 and STREAM-2 trials.

American heart journal·2025
Same author

Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2.

Circulation. Cardiovascular interventions·2024
Same author

Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Elevation Myocardial Infarction: STREAM-2 1-Year Mortality Follow-Up.

Circulation·2024

相关实验视频

Updated: Dec 5, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.6K

在急性心肌梗塞和心脏性休克患者中提拉金氨酸酸的作用:TRIUMPH随机对照试验.

1, John H Alexander, Harmony R Reynolds

  • 1Duke University, Durham, NC, USa.

JAMA
|March 28, 2007
PubMed
概括

在心肌梗塞 (MI) 后患有心脏性休克的患者中,提拉基宁没有改善存活率. 这项研究发现,提拉吉宁和安慰剂组之间的死亡率没有显著差异,这突显了对新疗法的需求.

更多相关视频

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.6K

相关实验视频

Last Updated: Dec 5, 2025

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.6K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.6K

科学领域:

  • 心脏病学 心脏病学
  • 临界护理医学 临界护理医学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 心肌梗塞 (MI) 后的心脏性休克是一种危及生命的疾病.
  • 系统性炎症和氧化 (NO) 的过度生产有助于冲击.
  • 之前的研究表明,NOS抑制可能有利于心脏性休克患者.

研究的目的:

  • 评估一氧化合成酶 (NOS) 抑制剂蒂拉金因的疗效,在患有急性心脏病性冲击并发症的急性心脏病性心脏病性冲击患者中.
  • 评估提拉吉宁对死亡率,冲击缓解和功能状态的影响.

主要方法:

  • 一个随机,双盲,安慰剂对照试验 (TRIUMPH) 涉及398名患者.
  • 患者接受了提拉吉宁 (L-N(G) -单甲基氨酸[L-NMMA]) 或安慰剂.
  • 主要终点是30天全因死亡率;次要终点包括冲击解消和6个月死亡率.

主要成果:

  • 与安慰剂相比,提拉基宁没有显著降低30天全因死亡率 (48%与42%相比).
  • 在提拉吉宁和安慰剂组中,冲击解消率和持续时间在提拉吉宁和安慰剂组之间类似.
  • 两种治疗手臂的六个月死亡率也相似.

结论:

  • 提拉吉宁的使用并没有改善MI后耐心心脏病性休克患者的死亡结果.
  • 高的早期死亡率凸显了这种疾病的严重性.
  • 在急性心脏病发作后治疗心脏病性休克的新疗法开发至关重要.